Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing
Reexamination Certificate
2004-04-23
2008-12-02
Romeo, David S (Department: 1647)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
C424S093700, C435S377000, C435S365000, C435S368000
Reexamination Certificate
active
07459152
ABSTRACT:
The present invention provides methods, compounds and kits for increasing the viability of cells. The methods involve treating cells that make up a tissue graft with erythropoietin before, during or after delivery or administration. The method can employ cells of different types, including cells of neural or paraneural origin, such as adrenal chromaffin cells. Also useful are cell lines grown in vitro. Cells not of neural or paraneural origin, such as fibroblasts, may also be used following genetic alteration to express a desired neural product such as a neurotransmitter or a neuronal growth factor. The method is used to treat neurological diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease, epilepsy, and traumatic brain or spinal cord injury.
REFERENCES:
patent: 4703008 (1987-10-01), Lin
patent: 5082670 (1992-01-01), Gage et al.
patent: 5441868 (1995-08-01), Lin
patent: 5512661 (1996-04-01), Shooter et al.
patent: 5547933 (1996-08-01), Lin
patent: 5612211 (1997-03-01), Wilson et al.
patent: 5618531 (1997-04-01), Cherksey
patent: 5618698 (1997-04-01), Lin
patent: 5621080 (1997-04-01), Lin
patent: 5650148 (1997-07-01), Gage et al.
patent: 5650298 (1997-07-01), Bujard et al.
patent: 5653975 (1997-08-01), Baetge et al.
patent: 5656481 (1997-08-01), Baetge et al.
patent: 5750376 (1998-05-01), Weiss et al.
patent: 5753506 (1998-05-01), Johe
patent: 5756349 (1998-05-01), Lin
patent: 5773569 (1998-06-01), Wrighton et al.
patent: 5798113 (1998-08-01), Dionne et al.
patent: 5800828 (1998-09-01), Dionne et al.
patent: 5830851 (1998-11-01), Wrighton et al.
patent: 5856298 (1999-01-01), Strickland
patent: 5888772 (1999-03-01), Okasinski et al.
patent: 5955422 (1999-09-01), Lin
patent: 5965125 (1999-10-01), Mineau-Hanschke
patent: 5986047 (1999-11-01), Wrighton et al.
patent: 5994313 (1999-11-01), Crabtree et al.
patent: 6083523 (2000-07-01), Dionne et al.
patent: 6165783 (2000-12-01), Weiss et al.
patent: 6183965 (2001-02-01), Verdine et al.
patent: 6254865 (2001-07-01), Freed et al.
patent: 6271436 (2001-08-01), Piedrahita et al.
patent: 6277820 (2001-08-01), Rosenthal et al.
patent: 6284539 (2001-09-01), Bowen et al.
patent: 6368854 (2002-04-01), Weiss et al.
patent: 6369294 (2002-04-01), Piedrahita et al.
patent: 6395546 (2002-05-01), Zobel et al.
patent: 6419920 (2002-07-01), Mineau-Hanschke
patent: 6444205 (2002-09-01), Dinsmore
patent: 6451306 (2002-09-01), Tuszynski et al.
patent: 6472181 (2002-10-01), Mineau-Hanschke
patent: 6497872 (2002-12-01), Weiss et al.
patent: 6610540 (2003-08-01), Csete et al.
patent: 6638501 (2003-10-01), Bjornson et al.
patent: 2003/0103949 (2003-06-01), Carpenter et al.
patent: 2004/0092444 (2004-05-01), Digicaylioglu et al.
patent: WO 93/01275 (1993-01-01), None
patent: WO 94/02593 (1994-02-01), None
patent: WO 94/10292 (1994-05-01), None
patent: WO 94/25055 (1994-11-01), None
patent: WO 96/04368 (1996-02-01), None
patent: WO 97/44442 (1997-11-01), None
patent: WO 98/30678 (1998-07-01), None
Drucker and Diaz, Cell Mol Neurobiol, Jun. 2004, 24(3):301-316.
Maiese et. al., JAMA, Jan. 5, 2005, 293(1):90-95.
Lindvall and Bjorklund, NeuroRX, Oct. 2004, 1(4):382-93.
Schierle et. al.Nature Med, Jan. 1999, 5(1):97-100.
Widner et. al., NEJM, Nov. 26, 1992, 327(22)1556-63.
Chong et. al., J Neurosci Res, Mar. 2003, 71(5):659-69.
Ehrenreich et. al., Molecular Medicine, 2002, 8(8):495-505.
Gorio et. al., Proc Natl Acad Sci U S A, Jul. 9, 2002, 99(14):9450-5.
Genc et al., (2001), Neuroscience Letters 298:139-141.
Verhoeyen and Cosset, (2004) Blood 103(9): 3248-3249.
Brines et al., Proc Natl Acad Sci U S A. Sep. 12, 2000;97(19):10526-10531.
Animal Care and Use,(Oct. 11, 2001), http://www.jhu.edu/animalcare/rat.htm, Accessed Oct. 3, 2007.
Leksell and Jernberg, “Stereotaxis and Tomography,”Acta Neurochir. 52:1-7, 1980. Published by Springer-Verlag.
“Neural Grafting in the Mammalian CNS,” Bjorklun and Stenveni, eds.; Das, Ch. 3 pp. 23-30; Freed Ch. 4, pp. 31-40; Stenevi et al., Ch. 5, pp. 41-49; Brundin et al., Ch. 6, pp. 51-59; David et al., Ch. 7, pp. 61-69; and Seiger, Ch. 8, pp. 71-77, 1985. Published by Elsevier.
Burns et al., “A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine,”Proc. Natl. Acad. Sci. USA, 80:4546-4550, Jul. 1983.
Bankiewicz et al., Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP),Life Sci., 39:7-16, 1986. Published by Pergamon Press.
Leksell et al., “A new fixation device for the Leksell stereotaxic system,”J. Neurosurg. 66:626-629, 1987.
Duncan et al., “Transplantation of oligodendrocytes and Schwann cells into the spinal cord of the myelin-deficient rat,”J. Neurocytology, 17:351-360, 1988. Published by Chapman and Hall, Ltd.
Burns et al., “The clinical syndrome of striatal dopamine deficiency,”N. Engl. J. Med., 312(22), 1418-1421, May 30, 1985. Published by the Massachusetts Medical Society.
Wolff et al., “Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease,”Proc. Natl. Acad. Sci USA, 86:9011-9014, Nov. 1989.
Neural Grafting: Repairing the Brain and Spinal cord, Chapter 4: “General Features of Neural Grafting,” pp. 39-57; Pub. by Congress of the U.S., Office of Technology and Assessment, Washington, DC, Oct. 1990.
Sagen, et al., “Monoaminergic Neural Transplants Prevent Learned Helplessness in a Rat Depression Model,”Biol Psychiatry, 28(12), pp. 1037-1048, 1990. Published by the Society of Biological Psychiatry.
Bankiewicz et al., “The effect of fetal mesencephalon implants on primate MPTP-induced parkinsonism,”J. Neurosurg., 72:231-244, Feb. 1990.
Taylor et al., “Improvements in MPTP-induced object retrieval deficits and behavioral deficits after fetal nigral grafting in monkeys,”Prog. Brain Res., 82:543-559, 1990. Published by Elsevier.
Bjorklund et al., “Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants,”Brain Res., 177:555-560, 1979. Published by Elsevier.
Lindvall et al., “Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease,”Science, 247:574-577, Feb. 2, 1990.
Freed, “Substantia nigra grats and Parkinson's disease: from animal experiments to human therapeutic trials,” Restor. Neurol. Neurosci., 3:109-134 (1991).
Fisher et al., “Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-dopa,” Neuron, 6:371-380, Mar. 1991.
Gage and Fisher, “Intracerebral Grafting: A tool for the Neurobiologist,”Neuron, 6:1-12, Jan. 1991. Published by Cell Press.
Lindvall et al., “Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease,”Arch. Neurol., 46:615-631, Jun. 1989. Published by the American Medical Association.
Widner et al., “Bilateral fetal mesencephalic grafting in two patients with Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine,”New Engl. J. Med., 327(22):1556-1563, Nov. 26, 1992. Published by the Massachusetts Medical Society.
Sortwell, et al., “Induction of Antidepressive Activity by Monoaminergic Transplants in Rat Neocortex,”Pharmacol Biochem Behav, 46(1), pp. 225-230, 1993. Published by Pergamon Press Ltd.
Sortwell, et al., “In Vivo Release of Catecholamines from Xenogeneic Chromaffin Cell Grafts with Antidepressive Activity,”Exp Neurol130(1), pp. 1-8, 1994. Published by Academic Press, Inc.
Sortwell, et al., “Chromaffin cell xenografts in the rat neocortex can produce antidepressive activity in the forced swimming test,”Exp Brain Res, 103(1) 59-69, 1995. Published by Springer-Verlag.
Fawcett, et al., “Dopaminergic neuronal survival and the effects of bFGF in explant, three dimensional a
Collier Timothy J.
Sortwell Caryl E.
Foley & Lardner LLP
Gamett Daniel C
Romeo David S
Rush University Medical Center
LandOfFree
Erythropoietin administration to improve graft survival does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Erythropoietin administration to improve graft survival, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Erythropoietin administration to improve graft survival will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4033104